We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-15.41%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$343M
AUM Growth
-$87.3M
Cap. Flow
+$1.65M
Cap. Flow %
0.48%
Top 10 Hldgs %
91.51%
Holding
19
New
1
Increased
7
Reduced
7
Closed
–
Avg Time Held
4.6 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
4.6 quarters

Top Buys

Rank Stock Value
1
OMGA icon
Omega Therapeutics, Inc. Common Stock
OMGA
+$20.3M
2
PLRX icon
Pliant Therapeutics
PLRX
+$2.48M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$237K
4
ONCR
Oncorus, Inc.
ONCR
+$228K
5
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$226K

Top Sells

Rank Stock Value
1
RPTX icon
Repare Therapeutics
RPTX
+$9.91M
2
IMA icon
ImageneBio Inc
IMA
+$6.05M
3
KROS icon
Keros Therapeutics
KROS
+$3.69M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.64M
5
KZR icon
Kezar Life Sciences
KZR
+$474K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$67.9M 19.81%
2,862,059
+10,050
+0.4% +$237K
2021 Q1
2 quarters
RPTX icon
2
DELISTED
Repare Therapeutics
RPTX
$58.6M 17.1%
2,232,783
-306,861
-12% -$9.91M
2020 Q2
5 quarters
CGEM icon
3
Cullinan Oncology
CGEM
$962M
$50.7M 14.79%
2,244,841
+2,000
+0.1% +$53.5K
2021 Q1
2 quarters
PLRX icon
4
Pliant Therapeutics
PLRX
$61.1M
$41.9M 12.24%
2,484,724
+116,836
+5% +$2.48M
2020 Q2
5 quarters
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$20M 5.85%
2,592,602
+6,616
+0.3% +$56.7K
2021 Q2
1 quarter
OMGA icon
6
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$19.9M 5.81%
+1,055,882
New +$20.3M
2021 Q3
0 quarters
LRMR icon
7
Larimar Therapeutics
LRMR
$263M
$17.5M 5.1%
1,515,148
– –
2020 Q2
5 quarters
ONCR
8
DELISTED
Oncorus, Inc.
ONCR
$16.4M 4.79%
1,755,979
+20,000
+1% +$228K
2020 Q4
3 quarters
INZY icon
9
DELISTED
Inozyme Pharma
INZY
$10.7M 3.11%
920,264
-7,000
-0.8% -$109K
2020 Q3
4 quarters
AKUS
10
DELISTED
Akouos Inc
AKUS
$9.96M 2.91%
858,027
– –
2020 Q2
5 quarters
ORTX
11
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.39M 2.74%
408,197
– –
2019 Q3
8 quarters
DTIL icon
12
Precision BioSciences
DTIL
$180M
$7.46M 2.18%
21,558
-166
-0.8% -$56.3K
2019 Q3
8 quarters
FRLN
13
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$4.87M 1.42%
95,165
+3,175
+3% +$226K
2020 Q3
4 quarters
IMA icon
14
ImageneBio Inc
IMA
$48.2M
$3.98M 1.16%
26,250
-41,646
-61% -$6.05M
2021 Q1
2 quarters
CRVS icon
15
Corvus Pharmaceuticals
CRVS
$845M
$803K 0.23%
165,927
-553,205
-77% -$1.64M
2019 Q3
8 quarters
OVID icon
16
Ovid Therapeutics
OVID
$471M
$785K 0.23%
233,510
+15,000
+7% +$54.7K
2019 Q3
8 quarters
GTHX icon
17
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$671K 0.2%
50,000
– –
2020 Q2
5 quarters
KZR icon
18
DELISTED
Kezar Life Sciences
KZR
$648K 0.19%
7,500
-7,168
-49% -$474K
2019 Q3
8 quarters
KROS icon
19
Keros Therapeutics
KROS
$230M
$500K 0.15%
12,627
-103,779
-89% -$3.69M
2020 Q2
5 quarters

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, CHI Advisors held 19 positions worth $343M, down 20% from $430M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

CHI Advisors's Q3 2021 filing shows 1 new, 7 increased and 7 reduced positions. Its largest new stake was Omega Therapeutics, Inc. Common Stock: 1,055,882 shares worth $19.9M. The largest sale was Repare Therapeutics, an estimated $9.91M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • CHI Advisors's largest Q3 2021 buy was Omega Therapeutics, Inc. Common Stock: 1,055,882 shares worth $19.9M.
  • CHI Advisors added most to Pliant Therapeutics in Q3 2021, an estimated $2.48M increase.
  • CHI Advisors's biggest Q3 2021 reduction was Repare Therapeutics, cutting an estimated $9.91M.
  • CHI Advisors's ten largest holdings make up 92% of its $343M portfolio in Q3 2021.
  • CHI Advisors opened 1 new position and closed 0 in Q3 2021.
  • CHI Advisors's portfolio value fell 20% quarter-over-quarter to $343M.

Based on CHI Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.